IPMN-associated pancreatic cancer

• Verfasst von: Kaiser, Jörg [VerfasserIn]
• Verfasst von: Scheifele, Cornelius [VerfasserIn]
• Verfasst von: Hinz, Ulf [VerfasserIn]
• Verfasst von: Leonhardt, Carl-Stephan [VerfasserIn]
• Verfasst von: Hank, Thomas [VerfasserIn]
• Verfasst von: König, Anna-Katharina [VerfasserIn]
• Verfasst von: Tjaden, Christin [VerfasserIn]
• Verfasst von: Hackert, Thilo [VerfasserIn]
• Verfasst von: Bergmann, Frank [VerfasserIn]
• Verfasst von: Büchler, Markus W. [VerfasserIn]
• Verfasst von: Strobel, Oliver [VerfasserIn]
• Titel: IPMN-associated pancreatic cancer
• Titelzusatz: survival, prognostic staging and impact of adjuvant chemotherapy
• Verf.angabe: Joerg Kaiser, Cornelius Scheifele, Ulf Hinz, Carl-Stephan Leonhardt, Thomas Hank, Anna-Katharina Koenig, Christine Tjaden, Thilo Hackert, Frank Bergmann, Markus W. Büchler, Oliver Strobel
• Jahr: 2022
• Umfang: 12 S.
• Fussnoten: Erstmals am 11. Dezember 2021 online zugänglich ; Gesehen am 21.12.2022
• Titel Quelle: Enthalten in: European journal of surgical oncology
• Ort Quelle: Burlington, Mass. : Harcourt, 1995
• Jahr Quelle: 2022
• Band/Heft Quelle: 48(2022), 6, Seite 1309-1320
• ISSN Quelle: 1532-2157
• DOI: doi:10.1016/j.ejso.2021.12.009
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: Colloid carcinoma
• Sach-SW: IPMN
• Sach-SW: Pancreatic ductal adenocarcinoma
• Sach-SW: Prognostic factors
• Sach-SW: Staging
• Sach-SW: Survival
• K10plus-PPN: 1828247243

Abstract

Background - Intraductal papillary mucinous neoplasm (IPMN)-associated carcinoma is a subtype of pancreatic cancer for which prognostic factors, the validity of the AJCC/UICC staging system and the role of adjuvant chemotherapy remain unknown. - Materials and methods - Clinicopathological, treatment and follow-up data of patients with IPMN-associated carcinoma undergoing resection between 2002 and 2018 were analyzed. Uni- and multivariable survival analyses were performed to identify prognostic factors. - Results - Of 424 patients undergoing resection for IPMN-associated carcinoma, 77% patients had pancreatic ductal adenocarcinoma (IPMN-PDAC) and 23% had colloid carcinoma (IPMN-CC). Compared to IPMN-CC, IPMN-PDAC was diagnosed at more advanced tumor stages, more frequently involved lymph nodes, more frequently showed poor differentiation and were associated with higher rates of R1 resections. Resected IPMN-PDAC showed markedly shorter median overall survival than IPMN-CC (26.7 months vs. 91.3 months). The current AJCC/UICC staging system was validated for IPMN-associated carcinoma and for both of its subtypes. In multivariable analysis age ≥70 years, diabetes mellitus, high levels of Ca 19-9, IPMN-PDAC subtype, G3 tumors and higher AJCC/UICC stage were independently associated with shorter survival. Adjuvant therapy was not associated with improved survival in IPMN-associated carcinoma. Overall survival was comparable in patients receiving vs. not receiving adjuvant therapy. - Conclusions - Survival after resection of IPMN-associated carcinoma depends on tumor stage, on histologic tumor subtype, grading, and Ca 19-9 levels. The current 8th edition of the AJCC/UICC staging system is applicable for IPMN-associated carcinoma and for both of its subtypes IPMN-PDAC and IPMN-CC. The role of adjuvant therapy for IPMN-associated carcinoma remains unclear.